MobiHealth News April 22, 2025
Jessica Hagen

The company’s patch uses intradermal electrochemical sensors to monitor glucose levels and provide metabolic insights to individuals with type 2 diabetes not on insulin.

Biolinq, a health technology company developing precision multi-analyte wearable biosensors for metabolic health, announced it secured $100 million in Series C funding.

Alpha Wave Ventures led the round with participation from existing investors AXA IM Alts, M Ventures, LifeSci Venture Partners, RiverVest Venture Partners, Hikma Ventures, Taisho Pharmaceutical, Features Capital and Aphelion Capital.

WHAT IT DOES

Biolinq offers a wearable patch that evaluates glucose levels and provides insights into metabolic health for individuals with type 2 diabetes who are not on insulin.

The patch uses small electrochemical sensors to measure glucose levels from the...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Digital Health, Investments, Technology, Trends, Wearables
Related Articles:
FDA guidance eases wearables oversight. But experts have questions about what’s next.
Dual-Sensor Smartwatch May Boost Detection of Silent AF
Two App Updates Make The Apple Watch Even Better For Fitness Tracking
The Smart Sleep Alarm Is The Holy Grail Of Health Tracking - 2
Sleep trackers are popular, but what do they really measure?

Share Article